You are here

Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)

MIRAMAR, FL, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Regentys Corporation, a clinical stage regenerative medicine company focused on the treatment of inflammatory bowel diseases such as Ulcerative Colitis (“UC”) and Crohn’s Disease, was granted a Notice of Allowance for its patent application entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy” in Japan:
Tuesday, February 19, 2019 - 09:00